# A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

> **NCT05674526** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Wugen, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **BIOLOGICAL:** WU-NK-101 - Dose Escalation
- **DRUG:** Cetuximab - Dose Escalation
- **BIOLOGICAL:** WU-NK-101 - Cohort Expansion
- **BIOLOGICAL:** Cetuximab - Cohort Expansion

## Key facts

- **NCT ID:** NCT05674526
- **Lead sponsor:** Wugen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05674526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05674526, "A Phase 1b Study of WU-NK-101 in Combination With Cetuximab". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05674526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*